Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Apartment Investment and Management CoTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs Neurocrine Biosciences Inc — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Neurocrine Biosciences Inc trades at $158.62 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 43.8× Apartment Investment and Management Co's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.

AIVNBIX
Market Cap
$376.16M$16.46B
Sector
Real EstateHealth
52-Week High
$7.93$185.50
52-Week Low
$2.59$123.10
Enterprise Value
$738.32M$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.62, down 1.5% recently, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $1.06, beating expectations, but revenue declined to $138.49M in 2025. Valuation ratios show a low P/B of 0.76, suggesting potential undervaluation, while a net income margin of 400.05% reflects significant one-time tax benefits. Cash flow improved with a net inflow of $234M in 2025.

Outlook is mixed: strong profitability metrics and a scheduled dividend in 2026 offer upside, but inconsistent earnings history and revenue volatility pose risks. Analyst consensus is cautious with 33% buy ratings. Investors should weigh the attractive valuation against operational challenges in the real estate sector.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX